We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
- Authors
Ferrandina, Gabriella; Mey, Valentina; Nannizzi, Sara; Ricciardi, Simona; Petrillo, Marco; Ferlini, Cristiano; Danesi, Romano; Scambia, Giovanni; Del Tacca, Mario
- Abstract
Gemcitabine (2',2'-difluorodeoxycytidine) (GEM) is one of the most actively investigated drugs in ovarian cancer. Many molecular mechanisms have been proposed to be involved in GEM sensitivity/resistance including the equilibrative nucleoside transporter-1 (hENT1), the concentrative nucleoside transporter-1 (hCNT1), and deoxycytidine kinase (dCK). The expression of the ribonucleotide reductase regulatory subunits M1 (RRM1) and M2 (RRM2), and the catabolic enzymes 5'nucleotidase (5'NT), and cytidine deaminase (CDA) play also an important role. The aim of the study is to investigate the potential clinical role of hENT1, hCNT1, dCK, RRM1, RRM2, CDA, and 5'NT in a single institutional series of 25 primary ovarian carcinomas.
- Publication
Cancer chemotherapy and pharmacology, 2010, Vol 65, Issue 4, p679
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-009-1073-y